Home › Psoriasis › Indiana › Indianapolis
Psoriasis clinical trials in Indianapolis, IN
3 studies for Psoriasis are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RecruitingPhase 4
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield · 14 mi away
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RecruitingPhase 3
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
RecruitingPhase 3
- Vanda Investigational Site, Indianapolis
About Psoriasis
Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. Some people also get psoriasis arthritis.
More about Psoriasis on MedlinePlus
Psoriasis trials in other cities
- Trenton, NJ7 studies
- Philadelphia, PA6 studies
- Cleveland, OH6 studies
- Fremont, CA5 studies
- Huntington Beach, CA5 studies
- San Antonio, TX5 studies
- New York City, NY5 studies
- Newton, MA5 studies
- Houston, TX4 studies
- Birmingham, AL4 studies
- Sacramento, CA3 studies
- Miami, FL3 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)24 studies
- Heart Failure24 studies
- Obesity22 studies
- Breast Cancer19 studies
- Ovarian Cancer18 studies
- Metastatic Cancer17 studies
- Colorectal Cancer17 studies
- Cardiovascular Disease16 studies
- Lung Cancer16 studies
- Type 1 Diabetes14 studies
- Overweight14 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.